Melanocyte protein PMEL (gp100) CD4+ T-cell epitopes (aa44-59 and aa174-190) presented by HLA class II (gp100 CD4 epitopes (aa44-59/174-190))

The target consists of specific MHC class II-restricted epitopes derived from the Melanocyte protein PMEL, commonly known as gp100, specifically encompassing amino acid residues 44-59 (WNRQLYPEWTEAQRLD) and 174-190 (TGRAMLGTHTMEVTVYH). These peptides are processed and presented by Human Leukocyte Antigen (HLA) class II molecules, such as HLA-DR4, on the surface of melanocytes, melanoma cells, and antigen-presenting cells (Li et al., 1999, Cancer Research). gp100 is a type I transmembrane protein essential for the structural maturation of melanosomes, and its high expression in melanoma makes it a primary target for cancer immunotherapy (UniProt P40967). Recognition of these specific epitopes by CD4+ T-cells is crucial for orchestrating a robust immune response, as helper T-cells provide necessary cytokines and signals for the activation and long-term memory of CD8+ cytotoxic T-cells (Rosenberg et al., 2004, Nature Medicine). Therapeutic interventions targeting these epitopes primarily include peptide-based vaccines and TCR-engineered T-cell therapies designed to treat metastatic melanoma. Clinical challenges include the potential for autoimmune destruction of normal melanocytes, leading to vitiligo, and the requirement for specific HLA-matching in patients.

Other names

gp100:44-59gp100:174-190PMEL epitopesSilver locus protein homolog epitopesMelanocyte-specific antigen gp100 CD4 epitopesME20-SSIEL

Stimulation of antigen-specific CD4+ helper T-lymphocytes to enhance anti-tumor immunity and support CD8+ cytotoxic T-cell activity.